UA80741C2 - Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis - Google Patents

Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis Download PDF

Info

Publication number: UA80741C2
Authority: UA; Ukraine
Prior art keywords: estrogen; progestin; endometriosis; treatment; combination
Prior art date: 2003-02-05

Application number

UAA200508473A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-05

Filing date

2004-03-02

Publication date

2007-10-25

2004-03-02 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2007-10-25 Publication of UA80741C2 publication Critical patent/UA80741C2/uk

Links

239000000262 estrogen Substances 0.000 title claims abstract description 43
201000009273 Endometriosis Diseases 0.000 title claims abstract description 33
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 29
239000000583 progesterone congener Substances 0.000 title claims abstract description 29
239000003886 aromatase inhibitor Substances 0.000 title claims abstract description 28
229940122815 Aromatase inhibitor Drugs 0.000 title claims abstract description 24
238000000034 method Methods 0.000 claims abstract description 4
229940011871 estrogen Drugs 0.000 claims description 41
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 13
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 13
229960002568 ethinylestradiol Drugs 0.000 claims description 13
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 11
229960004400 levonorgestrel Drugs 0.000 claims description 10
229960002932 anastrozole Drugs 0.000 claims description 7
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 7
229940126601 medicinal product Drugs 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
229940053934 norethindrone Drugs 0.000 claims description 5
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 5
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 4
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 4
229960001390 mestranol Drugs 0.000 claims description 4
229960004976 desogestrel Drugs 0.000 claims description 3
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 3
229960003881 letrozole Drugs 0.000 claims description 3
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 3
229960000417 norgestimate Drugs 0.000 claims description 3
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 3
-1 pentrozole Chemical compound 0.000 claims description 3
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 2
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 2
125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
229950011548 fadrozole Drugs 0.000 claims description 2
229960004421 formestane Drugs 0.000 claims description 2
229960001652 norethindrone acetate Drugs 0.000 claims description 2
229960001771 vorozole Drugs 0.000 claims description 2
XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 claims description 2
238000012876 topography Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract description 3
208000002193 Pain Diseases 0.000 description 15
230000000694 effects Effects 0.000 description 12
208000024891 symptom Diseases 0.000 description 11
239000002552 dosage form Substances 0.000 description 10
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 8
229930182833 estradiol Natural products 0.000 description 8
229960005309 estradiol Drugs 0.000 description 8
239000003826 tablet Substances 0.000 description 8
239000000556 agonist Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
102000006771 Gonadotropins Human genes 0.000 description 6
108010086677 Gonadotropins Proteins 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000002622 gonadotropin Substances 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
206010062767 Hypophysitis Diseases 0.000 description 5
208000000450 Pelvic Pain Diseases 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
230000007423 decrease Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
229940127234 oral contraceptive Drugs 0.000 description 5
239000003539 oral contraceptive agent Substances 0.000 description 5
210000001672 ovary Anatomy 0.000 description 5
210000003635 pituitary gland Anatomy 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
206010060800 Hot flush Diseases 0.000 description 4
238000013459 approach Methods 0.000 description 4
229940046844 aromatase inhibitors Drugs 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
210000004696 endometrium Anatomy 0.000 description 4
229940094892 gonadotropins Drugs 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
235000012431 wafers Nutrition 0.000 description 4
208000033830 Hot Flashes Diseases 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
229960000766 danazol Drugs 0.000 description 3
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000002357 endometrial effect Effects 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
102000014654 Aromatase Human genes 0.000 description 2
108010078554 Aromatase Proteins 0.000 description 2
206010006313 Breast tenderness Diseases 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
206010046788 Uterine haemorrhage Diseases 0.000 description 2
206010046910 Vaginal haemorrhage Diseases 0.000 description 2
206010047791 Vulvovaginal dryness Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001548 androgenic effect Effects 0.000 description 2
DKVSUQWCZQBWCP-QAGGRKNESA-N androsta-1,4,6-triene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 DKVSUQWCZQBWCP-QAGGRKNESA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000037182 bone density Effects 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
229960005352 gestodene Drugs 0.000 description 2
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
208000000509 infertility Diseases 0.000 description 2
230000036512 infertility Effects 0.000 description 2
231100000535 infertility Toxicity 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
206010022437 insomnia Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000000757 progestagenic effect Effects 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000002271 resection Methods 0.000 description 2
230000037394 skin elasticity Effects 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
LUJVUUWNAPIQQI-UHFFFAOYSA-N (+)-androsta-1,4-diene-3,17-dione Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 LUJVUUWNAPIQQI-UHFFFAOYSA-N 0.000 description 1
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
YEWSFUFGMDJFFG-QAGGRKNESA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-2,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 YEWSFUFGMDJFFG-QAGGRKNESA-N 0.000 description 1
MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 1
150000000319 19-nortestosterones Chemical class 0.000 description 1
PJMNEPMSGCRSRC-IEVKOWOJSA-N 4-androstene-3,6,17-trione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=O)C2=C1 PJMNEPMSGCRSRC-IEVKOWOJSA-N 0.000 description 1
OSVMTWJCGUFAOD-UHFFFAOYSA-N 4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1O OSVMTWJCGUFAOD-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000016216 Choristoma Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
208000004483 Dyspareunia Diseases 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101000573451 Homo sapiens Msx2-interacting protein Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
102100026285 Msx2-interacting protein Human genes 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
ZUQAPLKKNAQJAU-UHFFFAOYSA-N acetylenediol Chemical compound OC#CO ZUQAPLKKNAQJAU-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
229960005471 androstenedione Drugs 0.000 description 1
PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
229950004810 atamestane Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000037416 cystogenesis Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002162 estranes Chemical class 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
238000009164 estrogen replacement therapy Methods 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
230000001456 gonadotroph Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
239000000025 natural resin Substances 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
208000011735 pelvic symptom Diseases 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
150000003128 pregnanes Chemical class 0.000 description 1
238000004321 preservation Methods 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000037390 scarring Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960005353 testolactone Drugs 0.000 description 1
BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UAA200508473A 2003-02-05 2004-03-02 Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis UA80741C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0302572.3A GB0302572D0 (en)	2003-02-05	2003-02-05	Method of treatment
PCT/GB2004/000414 WO2004069260A1 (en)	2003-02-05	2004-02-03	Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis

Publications (1)

Publication Number	Publication Date
UA80741C2 true UA80741C2 (en)	2007-10-25

Family

ID=9952433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200508473A UA80741C2 (en)	2003-02-05	2004-03-02	Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis

Country Status (29)

Country	Link
US (2)	US7910570B2 (da)
EP (2)	EP1857111A3 (da)
JP (2)	JP4658918B2 (da)
KR (1)	KR101075929B1 (da)
CN (1)	CN100393360C (da)
AR (1)	AR043013A1 (da)
AT (1)	ATE374612T1 (da)
AU (1)	AU2004210184B2 (da)
BR (1)	BRPI0407039A (da)
CA (1)	CA2513910C (da)
CO (1)	CO5580789A2 (da)
CY (1)	CY1107816T1 (da)
DE (1)	DE602004009288T2 (da)
DK (1)	DK1589976T3 (da)
ES (1)	ES2293215T3 (da)
GB (1)	GB0302572D0 (da)
IL (1)	IL169583A0 (da)
IS (1)	IS2547B (da)
MX (1)	MXPA05008347A (da)
MY (1)	MY140723A (da)
NO (1)	NO20053626L (da)
NZ (1)	NZ541222A (da)
PL (1)	PL214680B1 (da)
PT (1)	PT1589976E (da)
RU (2)	RU2360681C2 (da)
TW (1)	TWI354556B (da)
UA (1)	UA80741C2 (da)
WO (1)	WO2004069260A1 (da)
ZA (1)	ZA200506221B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0302572D0 (en) *	2003-02-05	2003-03-12	Astrazeneca Ab	Method of treatment
CA2585832A1 (en) *	2004-10-04	2006-04-20	Wayne State University	Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus
WO2009075838A2 (en) *	2007-12-10	2009-06-18	Meditrina Pharmaceuticals, Inc.	Treatment of menorrhagia with aromatase inhibitor
DE102010003494A1 (de) *	2010-03-31	2011-10-06	Bayer Schering Pharma Aktiengesellschaft	Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (en) *	2011-01-14	2012-07-18	Université Catholique De Louvain	Implant comprising a core and a tube encasing the core
RU2541089C1 (ru) *	2013-11-22	2015-02-10	Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук	Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) *	2016-08-19	2016-10-05	Mereo Biopharma 2 Ltd	Dosage regimen for the treatment of endometriosis
CN109248166A (zh) *	2017-07-13	2019-01-22	国家卫生计生委科学技术研究所	阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko)	2022-11-22	2024-05-30	성균관대학교산학협력단	디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물
WO2024197239A1 (en) *	2023-03-23	2024-09-26	William Bologna	Bioadhesive compositions and a method of treating endometriosis with aromatase inhibitors without increased gonadatroprin production
US20240315958A1 (en) *	2023-03-23	2024-09-26	Chemo Research, S.L.	Method and device for providing effective contraception

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8813353D0 (en)	1988-06-06	1988-07-13	Ici Plc	Therapeutic product
IL93693A (en) *	1989-03-10	2000-01-31	Endorech Inc	Pharmaceutical compositions for the treatment of estrogen sensitive diseases
JP2602456B2 (ja)	1990-04-12	1997-04-23	雪印乳業株式会社	子宮内膜症治療剤
DE4344462C2 (de)	1993-12-22	1996-02-01	Schering Ag	Zusammensetzung für die Empfängnisverhütung
US5681817A (en)	1994-02-04	1997-10-28	The Medical College Of Hampton Roads	Treatment of ovarian estrogen dependent conditions
ID27922A (id)	1998-06-11	2001-05-03	Endorech Inc	KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US6265393B1 (en) *	1998-08-07	2001-07-24	Heinrichs William Leroy	Prevention of endometriosis signs or symptons
AU2002213198A1 (en)	2000-10-11	2002-04-22	Laura Kragie	Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
MXPA03006607A (es)	2001-01-26	2003-09-22	Upjohn Co	Metodo combinado para tratar trastornos dependientes de hormonas.
WO2002074315A1 (de)	2001-03-21	2002-09-26	Schering Aktiengesellschaft	Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
GB0120147D0 (en)	2001-08-17	2001-10-10	Metris Therapeutics Ltd	Treatment method
WO2003017974A1 (en)	2001-08-31	2003-03-06	Pantarhei Bioscience B.V.	Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
US20050079156A1 (en)	2001-11-06	2005-04-14	Grace Wong	Method of treating endometreosis
KR20040073572A (ko)	2002-01-22	2004-08-19	악조 노벨 엔.브이.	내인성 에스트로겐의 합성을 예방하는 약물의 투여와관련된 호소 증상의 치료에서의 티볼론
AU2003213956A1 (en) *	2002-04-03	2003-10-13	Jencap Research Ltd.	Improved hormone replacement therapy
CA2521305A1 (en)	2002-04-03	2003-10-09	Jencap Research Ltd.	Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
WO2003082336A1 (en) *	2002-04-03	2003-10-09	Jencap Research Ltd.	Female birth control method
WO2004003147A2 (en) *	2002-06-27	2004-01-08	Centocor, Inc.	Cngh0004 polypeptides, antibodies, compositions, methods and uses
GB0302572D0 (en) *	2003-02-05	2003-03-12	Astrazeneca Ab	Method of treatment

2003
- 2003-02-05 GB GBGB0302572.3A patent/GB0302572D0/en not_active Ceased
2004
- 2004-01-29 TW TW093101969A patent/TWI354556B/zh not_active IP Right Cessation
- 2004-02-03 PL PL377939A patent/PL214680B1/pl unknown
- 2004-02-03 NZ NZ541222A patent/NZ541222A/en not_active IP Right Cessation
- 2004-02-03 EP EP07016253A patent/EP1857111A3/en not_active Withdrawn
- 2004-02-03 AR ARP040100329A patent/AR043013A1/es not_active Application Discontinuation
- 2004-02-03 US US10/543,584 patent/US7910570B2/en not_active Expired - Fee Related
- 2004-02-03 ES ES04707574T patent/ES2293215T3/es not_active Expired - Lifetime
- 2004-02-03 BR BR0407039-9A patent/BRPI0407039A/pt not_active IP Right Cessation
- 2004-02-03 CN CNB2004800035630A patent/CN100393360C/zh not_active Expired - Fee Related
- 2004-02-03 AU AU2004210184A patent/AU2004210184B2/en not_active Ceased
- 2004-02-03 EP EP04707574A patent/EP1589976B1/en not_active Expired - Lifetime
- 2004-02-03 DE DE602004009288T patent/DE602004009288T2/de not_active Expired - Lifetime
- 2004-02-03 JP JP2006502229A patent/JP4658918B2/ja not_active Expired - Fee Related
- 2004-02-03 AT AT04707574T patent/ATE374612T1/de active
- 2004-02-03 MX MXPA05008347A patent/MXPA05008347A/es active IP Right Grant
- 2004-02-03 CA CA2513910A patent/CA2513910C/en not_active Expired - Fee Related
- 2004-02-03 RU RU2005127667/15A patent/RU2360681C2/ru not_active IP Right Cessation
- 2004-02-03 WO PCT/GB2004/000414 patent/WO2004069260A1/en not_active Ceased
- 2004-02-03 KR KR1020057014375A patent/KR101075929B1/ko not_active Expired - Fee Related
- 2004-02-03 DK DK04707574T patent/DK1589976T3/da active
- 2004-02-03 PT PT04707574T patent/PT1589976E/pt unknown
- 2004-02-04 MY MYPI20040307A patent/MY140723A/en unknown
- 2004-03-02 UA UAA200508473A patent/UA80741C2/uk unknown
2005
- 2005-07-07 IL IL169583A patent/IL169583A0/en not_active IP Right Cessation
- 2005-07-26 NO NO20053626A patent/NO20053626L/no not_active Application Discontinuation
- 2005-08-01 CO CO05075357A patent/CO5580789A2/es not_active Application Discontinuation
- 2005-08-03 ZA ZA200506221A patent/ZA200506221B/en unknown
- 2005-08-30 IS IS8008A patent/IS2547B/is unknown
2007
- 2007-11-29 CY CY20071101527T patent/CY1107816T1/el unknown
2008
- 2008-09-25 RU RU2008138166/15A patent/RU2008138166A/ru not_active Application Discontinuation
2010
- 2010-09-20 US US12/886,269 patent/US20110009373A1/en not_active Abandoned
- 2010-10-07 JP JP2010227516A patent/JP2011001388A/ja active Pending

Also Published As

Publication number	Publication date
NO20053626L (no)	2005-08-26
CA2513910C (en)	2012-04-03
CN100393360C (zh)	2008-06-11
GB0302572D0 (en)	2003-03-12
KR20050098296A (ko)	2005-10-11
KR101075929B1 (ko)	2011-10-26
DE602004009288T2 (de)	2008-07-10
EP1857111A2 (en)	2007-11-21
AU2004210184A1 (en)	2004-08-19
EP1589976B1 (en)	2007-10-03
EP1589976A1 (en)	2005-11-02
PT1589976E (pt)	2007-11-22
RU2360681C2 (ru)	2009-07-10
PL377939A1 (pl)	2006-02-20
TWI354556B (en)	2011-12-21
HK1082918A1 (en)	2006-06-23
RU2008138166A (ru)	2010-03-27
ZA200506221B (en)	2006-05-31
JP2011001388A (ja)	2011-01-06
CO5580789A2 (es)	2005-11-30
TW200503731A (en)	2005-02-01
AU2004210184B2 (en)	2007-01-04
IS8008A (is)	2005-08-30
CY1107816T1 (el)	2013-06-19
JP4658918B2 (ja)	2011-03-23
BRPI0407039A (pt)	2006-01-17
CN1747736A (zh)	2006-03-15
WO2004069260A1 (en)	2004-08-19
IL169583A0 (en)	2007-07-04
ES2293215T3 (es)	2008-03-16
CA2513910A1 (en)	2004-08-19
NZ541222A (en)	2008-12-24
RU2005127667A (ru)	2006-03-27
US7910570B2 (en)	2011-03-22
ATE374612T1 (de)	2007-10-15
US20110009373A1 (en)	2011-01-13
DK1589976T3 (da)	2007-12-27
EP1857111A3 (en)	2009-03-04
JP2006516602A (ja)	2006-07-06
MXPA05008347A (es)	2005-11-04
IS2547B (is)	2009-10-15
MY140723A (en)	2010-01-15
PL214680B1 (pl)	2013-09-30
DE602004009288D1 (de)	2007-11-15
AR043013A1 (es)	2005-07-13
US20060142256A1 (en)	2006-06-29

Publication	Publication Date	Title
US8415332B2 (en)	2013-04-09	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20110009373A1 (en)	2011-01-13	Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis
US20050143359A1 (en)	2005-06-30	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Słopień et al.	2018	Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age
EP2392333A1 (en)	2011-12-07	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Marcus	1996	Use of estrogen for prevention and treatment of osteoporosis
AU713467B2 (en)	1999-12-02	Use of antioestrogens for male birth control
HK1113546A (en)	2008-10-10	Composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen, and its use for the treatment of endometriosis
HK1082918B (en)	2008-02-15	Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis
Standard et al.	0	H3B 2K4
AU2011203526A1 (en)	2011-08-04	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens